Lush green lawns, sun-drenched, aesthetically designed buildings, rare blossoms in full bloom, and graceful white swans gliding across placid ponds together create an atmosphere of quiet grace at the group headquarters — a serene world seemingly detached from the outside rush.

The Mehta family, which leads the group, has a combined wealth of ₹1.33 lakh crore, according to the 2025 Fortune India-Waterfield Advisors study of India’s Top 100 Billionaires. Yet, when one meets chairman emeritus Sudhir Mehta, chairman Samir Mehta, or the next generation — Jinal, Varun, Aman and Shaan — one is struck by their modesty, warmth, and effortless simplicity. Behind the unassuming charm, however, lies an ambitious and aggressive business drive. Sudhir and Samir Mehta have taken a back seat, passing on the baton of managing the day-to-day business to their sons as part of a well-thought-out succession plan.

The next generation is driving the group on a fast-track mode, charting one of the boldest expansion paths in India Inc. The group is investing more than ₹1 lakh crore across pharmaceuticals, power, gas, as well as new ventures, including sports, hospitals and diagnostics, to double its revenues and profits within five years.

Take Torrent Pharmaceuticals, for instance. The company has spent over $1 billion on acquisitions alone in the past decade, apart from its latest landmark deal — the acquisition of JB Chemicals and Pharmaceuticals Ltd (at a valuation of ₹25,000 crore, announced on June 29, 2025), a marquee name with a four-decade-old legacy and some big domestic brands.

Even before the JB Chem acquisition, Torrent had risen rapidly from 22nd place to 7th among Indian pharmaceutical firms in just 10 years. “We have one of the highest growth rates among the Top 10 Indian pharma companies, and our vision is to become the third-largest within the next three-five years,” Aman Mehta, MD, Torrent Pharmaceuticals, told Fortune India last year, sitting on the patio of the family’s lush riverfront farmhouse overlooking the Sabarmati on a rainy monsoon morning. His words have proven prophetic. Before the next monsoon, which ended recently, Torrent broke into India’s Top 5 pharma companies, powered by the JB Chem acquisition — a testament to the Mehtas’ quiet determination and aggressive growth plans.

In FY25, Torrent Pharmaceuticals achieved net sales of ₹11,317 crore, registering a three-year compound annual growth rate (CAGR) of 10%, while its net profit soared to ₹1,911 crore, registering an impressive CAGR of 35%, according to database provider Capitaline. The company delivered a total shareholder return (TSR) of 34.3% during the same period, with return on capital employed (RoCE) at 27.1%. Each of its major export geographies — the U.S., Brazil, Germany, and the Rest of the World — contributes over 10% of revenues.

The Mehta family

India’s Best CEOs 2025: Aman Mehta’s Next-gen Growth Play for Torrent Pharma